The Global Galectin Inhibitor Therapeutics Market is at a pivotal junction in 2025. Galectins, a family of proteins that bind to beta-galactosides, have emerged as critical regulators in various pathological processes, including chronic inflammation, fibrotic tissue remodeling, and immune system evasion by cancer cells. As clinical trial data matures, particularly for Galectin-3 inhib... https://www.databridgemarketresearch.com/reports/global-galectin-inhibitor-therapeutics-market